Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director Robin Carr, PhD steps up to CSO from his previous position as CDO Stevenage, UK, April 20 2021 […]
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class scientists […]
https://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svg00proteinbarhttps://myricxbio.com/wp/wp-content/uploads/2023/09/MyricxBio_Web.svgproteinbar2020-11-16 07:49:432022-02-22 08:53:27Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Myricx Pharma Announces Board and Executive Appointments
Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director Robin Carr, PhD steps up to CSO from his previous position as CDO Stevenage, UK, April 20 2021 […]
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class scientists […]